| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Van Meervelt, Luc
KU Leuven
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (6/6 displayed)
- 2020Synthesis, structure and <i>in vitro</i> cytotoxicity testing of some 2-aroylbenzofuran-3-olscitations
- 2014High current density electrodeposition of silver from silver-containing liquid metal salts with pyridine-N-oxide ligandscitations
- 2012Crystal structures of low-melting ionic transition-metal complexes with N-alkylimidazole ligandscitations
- 2010Cobalt(II) complexes of nitrile-functionalized ionic liquidscitations
- 2009Pyrrolidinium Ionic Liquid Crystalscitations
- 2004Lanthanide(III) nitrobenzenesulfonates as new nitration catalysts: The role of the metal and of the counterion in the catalytic efficiencycitations
Places of action
| Organizations | Location | People |
|---|
article
Synthesis, structure and <i>in vitro</i> cytotoxicity testing of some 2-aroylbenzofuran-3-ols
Abstract
<jats:p>Five 2-aroyl-5-bromobenzo[<jats:italic>b</jats:italic>]furan-3-ol compounds (two of which are new) and four new 2-aroyl-5-iodobenzo[<jats:italic>b</jats:italic>]furan-3-ol compounds were synthesized starting from salicylic acid. The compounds were characterized by mass spectrometry and <jats:sup>1</jats:sup>H NMR and <jats:sup>13</jats:sup>C NMR spectroscopy. Single-crystal X-ray diffraction studies of four compounds, namely, (5-bromo-3-hydroxybenzofuran-2-yl)(4-fluorophenyl)methanone, C<jats:sub>15</jats:sub>H<jats:sub>8</jats:sub>BrFO<jats:sub>3</jats:sub>, (5-bromo-3-hydroxybenzofuran-2-yl)(4-chlorophenyl)methanone, C<jats:sub>15</jats:sub>H<jats:sub>8</jats:sub>BrClO<jats:sub>3</jats:sub>, (5-bromo-3-hydroxybenzofuran-2-yl)(4-bromophenyl)methanone, C<jats:sub>15</jats:sub>H<jats:sub>8</jats:sub>Br<jats:sub>2</jats:sub>O<jats:sub>3</jats:sub>, and (4-bromophenyl)(3-hydroxy-5-iodobenzofuran-2-yl)methanone, C<jats:sub>15</jats:sub>H<jats:sub>8</jats:sub>BrIO<jats:sub>3</jats:sub>, were also carried out. The compounds were tested for their <jats:italic>in vitro</jats:italic> cytotoxicity on the four human cancer cell lines KB, Hep-G2, Lu-1 and MCF7. Six compounds show good inhibiting abilities on Hep-G2 cells, with IC<jats:sub>50</jats:sub> values of 1.39–8.03 µ<jats:italic>M</jats:italic>.</jats:p>